INIS
cancer
100%
bladder
100%
patients
97%
muscles
69%
chemotherapy
60%
robots
60%
netherlands
60%
diseases
42%
surgery
33%
risks
30%
control
30%
fibrosis
30%
prostate
30%
radiotherapy
30%
quality of life
30%
reviews
30%
toxicity
26%
urinary tract
19%
pcr
15%
data
13%
prednisolone
10%
organs
10%
kidneys
10%
failures
10%
pain
10%
hazards
7%
hospitals
7%
metastases
7%
symptoms
7%
radiations
7%
Keyphrases
Netherlands
60%
Neoadjuvant Chemotherapy
60%
Robot-assisted Radical Cystectomy
57%
Muscle-invasive Bladder Cancer
44%
Robot-assisted
34%
Survival Outcomes
33%
Radical Cystectomy
33%
Rare Diseases
30%
Matching Study
30%
IgG4-related Retroperitoneal Fibrosis
30%
Case-control Matching
30%
Rituximab
30%
Invasive Risk
30%
Open Radical Cystectomy
30%
Pathological Response
30%
Successful Treatment
30%
High-risk Non-muscle-invasive Bladder Cancer
30%
Muscle-invasive
30%
Radiation Therapy for Prostate Cancer
30%
Radiotherapy
30%
Scoping Review
30%
Functional Quality
30%
Adverse Events
30%
Bladder Outlet Obstruction
30%
Lower Urinary Tract Symptoms
30%
Functional Outcome
30%
Quality of Life
30%
Confidence Interval
23%
Genitourinary Toxicity
18%
5-year Survival
17%
Medicine and Dentistry
Cystectomy
91%
Neoadjuvant Chemotherapy
60%
Muscle Invasive Bladder Cancer
45%
Rituximab
30%
Retroperitoneal Fibrosis
30%
Rare Disease
30%
Non Muscle Invasive Bladder Cancer
30%
Immunoglobulin G4
30%
Radiation Therapy
30%
Prostate Cancer
30%
Quality of Life
30%
Adverse Event
30%
Bladder Outlet Obstruction
30%
Organ Systems
15%
Prednisolone
15%
Renal Failure
15%
IgG4-Related Disease
15%
Humoral Immunity
15%
Case Presentation
15%
Treatment Response
15%
Retroperitoneum
15%
Obstruction
15%
Urinary Tract Function
13%
Lower Urinary Tract Symptom
8%
Recurrence Free Survival
8%
Overall Survival
8%
Hazard Ratio
6%
Retrospective Study
6%